Personalized brain cancer vax tested in humans
An experimental brain cancer vaccine developed at Duke University is being tested on patients at Duke and St. Vincent's Medical Center in Jacksonville, FL. The vaccine is made by extracting white blood cells from the patient and then mixing it with DNA that includes the genetic mutations that triggered the glioblastoma. "We think a significant reason these tumors are so hard to treat to begin with is they are so good at evading the immune system," said Kent New, the head of neurosurgery at an affiliate of St. Vincent's. New trained with Duke's John Sampson, who developed the personalized vaccine. Report
More stories about brain cancer
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
More Research Reports >>

SHARE
WITH: